01061.HK
Essex Bio-Technology Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 2.21
+3.76%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.9x
Market Cap
HKD 1.25B
MomentumView details →
1D Return
+3.76%
YTD Return
−41.51%
RSI (14)
37.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.9x
Market Cap
HKD 1.25B
RSI (14)
37.9
MomentumView details →
1D Return
+3.76%
YTD Return
−41.51%
Similar companies
Latest newsMore news →
Essex Bio-Technology declared an interim dividend of HK$0.05 per share for the six months ended June 2026, down from HK$0.07 in the prior year period.30d agoEssex Bio-Technology reported interim results for the six months ended June 2026, with revenue of HK$785 million, down 10.5% year-on-year, and net profit of HK$111 million, down 32.2%.30d agoYisheng Bio (01061) entered into a strategic cooperation framework agreement with Kureha Medical to expand their collaboration in regenerative medicine and wound repair across China, Southeast Asia, and Japan.43d ago